Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Ticagrelor 90 mg Tablet Formulations in Healthy Thai Subjects (Fasting)
TCTR20230206006Phase 1Completed
- Sponsor
- Sun Pharma
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of ticagrelor in coronary arteriosclerosis and myocardial infarction (MI) (2 arms), sponsored by Sun Pharma. Primary endpoint: Primary bioequivalence endpoints. Started Sep 2023; status: completed.
02
Drugs
ticagrelor
03
Conditions
coronary arteriosclerosismyocardial infarction (MI)
Beyond the preview
Go deeper on TCTR20230206006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230206006.